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Abstract Factors that regulate apolipoprotein E (apoE) se-
cretion by macrophages will have important effects on vessel
wall lipid flux and atherosclerosis. Macrophages express
the LDL receptor, which binds apoE with high affinity and
could thereby affect the net secretion of apoE from macro-
phages. In these studies, we demonstrate that treatment
of J774 macrophages transfected to constitutively express
a human apoE3 cDNA with simvastatin, to increase LDL
receptor activity, reduces the secretion of apoE. To further
examine the relationship between LDL receptor expression
and apoE secretion from macrophages, mouse peritoneal
macrophages (MPMs) were isolated from mice with consti-
tutively high expression of human LDL receptor to increase
overall LDL receptor expression by 2- to 3-fold. Cells with
increased LDL receptor expression also showed reduced
apoE secretion compared with MPMs with basal LDL recep-
tor expression. The effect of changes in LDL receptor ex-
pression on apoE secretion was isoform-specific, with
greater reduction of apoE4 compared with apoE3 secre-
tion and no reduction of apoE2 secretion, paralleling the
known affinity of each isoform for LDL receptor binding.
The effect of the LDL receptor on apoE secretion for each
isoform was further reflected in LDL receptor-dependent
changes in apoE-mediated cholesterol efflux. These re-
sults establish a regulatory interaction between two branches
of macrophage sterol homeostatic pathways that could fa-
cilitate a rapid response to changes in macrophage sterol
content relative to need.—Lucic, D., Z. H. Huang, D. S.
Gu, M. K. Altenburg, N. Maeda, and T. Mazzone. Regu-
lation of macrophage apoE secretion and sterol efflux by
the LDL receptor. J. Lipid Res. 2007. 48: 366–372.
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Studies using multiple models of animal atherosclerosis
have demonstrated that macrophage-derived apolipopro-
tein E (apoE) is important for maintaining normal vessel
wall lipid homeostasis. For example, selective deletion of
apoE expression in macrophages markedly accelerates
atherosclerosis in mouse models of atherosclerosis (1–3).
Factors that regulate macrophage apoE synthesis and
secretion, therefore, are of interest for gaining insight
into the pathophysiology of atherosclerosis. ApoE gene
transcription in macrophages responds significantly to
changes in macrophage sterol balance, and this response
is mediated by the liver X receptor element located in a
downstream enhancer (4–6). The macrophage apoE gene
also responds to cytokines and macrophage differentia-
tion state (7, 8). In addition to transcriptional regulation,
there are important loci for posttranscriptional and post-
translational regulation of macrophage apoE expression
(9). The importance of these regulatory loci is magnified
because a large percentage of newly synthesized apoE in
the macrophage is degraded before its secretion, and
the fraction of apoE secreted versus that degraded is sub-
ject to regulation (7, 9). For example, we have shown pre-
viously that macrophage sterol balance modulates the
stability and secretion of macrophage apoE at a posttrans-
lational locus (10). The expression of apoE in macro-
phages produces sterol efflux from macrophages in an
ABCA1-dependent and -independent manner, and the
macrophage apoE response to sterols at transcriptional
and posttranslational regulatory loci demonstrates its role
in a homeostatic regulatory loop for defending macro-
phage sterol balance (11–13).
We reported previously that macrophage proteoglycans
sequester newly synthesized apoE at the macrophage cell
surface and thereby modulate apoE secretion (14, 15).
Cell surface LDL receptors also sequester newly synthe-
sized apoE (16). As yet, however, there is no information
regarding the modulation of macrophage apoE secretion
by changes in macrophage LDL receptor expression. The
aim of the current studies was to address the role of
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macrophage LDL receptor expression for modulating
apoE secretion from macrophages. Because of the well-
known differences in human apoE isoform interaction
with the LDL receptor (17, 18), we also addressed apoE
isoform-specific effects. We used two models to investigate
the role of the LDL receptor. In one, macrophage choles-
terol synthesis was inhibited using simvastatin, thereby
increasing LDL receptor expression. In the second model,
we used mouse peritoneal macrophages (MPMs) from
human apoE2, apoE3, and apoE4 knockin mice with basal
or increased LDL receptor expression secondary to the
expression of an LDL receptor minigene that produces an
mRNA with increased half-life.
METHODS
Materials
Goat apoE antiserum was from International Immunology
Corp. (Marietta, GA). [35S]methionine was purchased from
Amersham Biosciences Corp. (Piscataway, NJ). All other materi-
als were from previously described sources (7–15).
Cell culture
Targeted replacement of the mouse apoE gene with three
human apoE alleles (apoE2, apoE3, and apoE4) has been de-
scribed by Maeda and coworkers (19). Mice homozygous for
these apoE isoforms were bred with mice heterozygous for tar-
geted replacement of the mouse LDL receptor gene with the
human LDL receptor minigene (17). This LDL receptor mini-
gene produces an mRNA with an increased half-life, leading to a
2- to 3-fold increase in LDL receptor transcript expression and
increased LDL receptor activity (17, 20). Cells isolated from each
of the human genotypes were named according to the apoE iso-
form expressed (E2, E3, and E4) and designated WT cells if they
had basal, or Ldlr cells if they had increased, LDL receptor ex-
pression. Mice at 12–14 weeks of age were euthanized, and MPMs
were harvested as described previously (21). The cells were plated
on six-well plates and maintained in 10% FBS in DMEM. Cells
were used for experiments 12–14 days after isolation.
J774 cells (which do not express an endogenous apoE gene)
were stably transfected to express a human apoE3 cDNA in a
constitutive manner under the control of the cytomegalovirus
promoter. The apoE expression construct and the method for
transfection have been described in detail (11).
For some experiments, cell surface proteoglycans were de-
pleted as described previously in detail (14, 15). Briefly, cells were
incubated in 4-methyl-umbelliferyl-b-D-xyloside at a final concen-
tration of 1 mM for 72 h to inhibit cellular proteoglycan synthesis.
Immediately after this incubation, cells were treated for 30 min
at 378C with heparinase at a final concentration of 3 U/ml. We
have shown previously that these treatments reduce cell surface
proteoglycans in macrophages by up to 80% (14, 15).
Quantitation of apoE synthesis and secretion
In some experiments, immunoblot analysis was performed on
cell culture supernatants to measure steady-state levels of apoE
released into the medium from macrophages. Immunoblot anal-
ysis was performed as described previously in detail, and the
results were quantitated using Zero D-Scan software (Scanalytics,
Inc., Fairfax, VA) (13). For the quantitative measurement of
apoE synthesis and secretion rates, a pulse-chase experimental
design was used as described previously in detail (9). Cells were
pulse-labeled with [35S]methionine for 30–45 min and chased for
the times indicated in the figures. At the indicated chase times,
cell media and lysates were used for quantitative immunoprecip-
itation of apoE as described previously (9). Quantitative immuno-
precipitations are based on total TCA-precipitable radioactivity;
therefore, they are already corrected for any differences in the
synthesis or secretion of total protein. After immunoisolation,
labeled apoE was resolved on SDS-polyacrylamide gels, and radio-
activity present in cellular and secreted apoE was quantitated
using an Amersham Biosciences phosphorimager and Image-
Quant software. Results are expressed as scanning units. The
percentage of apoE secreted was calculated by comparing radio-
activity in apoE present in the medium at each indicated chase
time with the total amount of radiolabeled apoE present in cells
immediately after labeling.
Measurement of sterol efflux
Cellular sterol was radiolabeled to equilibrium using 48 h
incubations in 1 mCi/ml [3H]cholesterol as described previously
(13, 15). Cells were placed in 0.1% BSA for measurement of
sterol efflux as described previously in detail (1–3, 15). Sterol
efflux is expressed as mg cholesterol released into the medium
per mg cell protein by correcting medium [3H]cholesterol (dpm)
with cellular cholesterol specific activity.
Other assays
Total cellular cholesterol was measured enzymatically (Wako
USA) in hexane-isopropanol extracts. Cell protein was measured
using a DC protein kit (Bio-Rad). LDL receptor protein level was
measured by immunoblot analysis as described previously (22).
mRNA levels for LDL receptor were quantitated by RT-PCR using
a probe and primer set for murine exon 1, which measures both
human and murine mRNA species by a method described
previously (17, 23).
Statistical analysis
The results of experiments representative of two to four
additional experiments with similar results are presented and
expressed as means 6 SD of triplicate determinations of each
group unless indicated otherwise. The significance of differences
was analyzed by ANOVA using SPSS.
RESULTS
For the experiments shown in Figs. 1, 2, simvastatin was
used to inhibit cellular cholesterol synthesis and thereby
increase LDL receptor expression (24, 25). After incuba-
tion with simvastatin (20–40 mM), LDL receptor protein
levels were increased 2- to 4-fold as measured by im-
munoblot analysis (data not shown). The data in Fig. 1
show the results of an experiment evaluating the effect of
simvastatin (over a range of doses) on the steady-state level
of apoE released into the medium from J774-E cells, which
constitutively express a human apoE3 cDNA. All doses of
simvastatin reduced medium apoE, with maximal reduc-
tion observed at 20 mM simvastatin. The data in Fig. 2 show
the effect of this dose of simvastatin on the percentage
secretion and cellular retention of newly synthesized apoE
in J774-E cells. After a 20 h incubation with or without
20 mM simvastatin, cells were pulse-labeled, and cells and
medium were harvested at 60 and 120 min chase times.
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There was no statistically significant difference in cellular
apoE at the end of the pulse (chase time 0) between cells
incubated with or without simvastatin (data not shown). At
each chase time, simvastatin significantly reduced apoE
secretion, consistent with the results in Fig. 1. The amount
of apoE retained in the cells at chase times 60 and 120 min
was not different in control and simvastatin-treated cells.
These results indicate that simvastatin treatment, with its
attendant increase in LDL receptor expression, reduced
the secretion of newly synthesized apoE3 in macrophages.
The apoE not secreted was not retained within cells and
therefore degraded; at 120 min, the amount of apoE de-
graded approximately doubled in cells incubated with
simvastatin compared with control cells (from 32 6 5% to
60 6 8%). Furthermore, this is a posttranscriptional effect,
as J774-E cells constitutively express a human apoE3 cDNA.
In addition to increasing LDL receptor expression, sim-
vastatin may alter other cell pathways based on its inhibition
of hydroxy methyl glutaryl-CoA reductase. Therefore, to
more specifically assess the effect of the LDL receptor on
apoE secretion from macrophages, we used MPMs from
mice with basal or constitutively increased expression of the
LDL receptor. Furthermore, MPMs from human apoE3,
apoE4, and apoE2 knockin mice were evaluated to de-
termine whether there were apoE isoform-specific effects of
the LDL receptor. The generation and characterization of
these mice has been reported previously in detail (17).
Figure 3 shows the results of a pulse-chase analysis of
apoE secretion and cellular retention in WT and Ldlr cells
for each of the apoE isoforms. As expected, LDL receptor
mRNA levels were 2- to 4-fold higher in LDLr compared
with WT cells (data not shown). For apoE3 (Fig. 3, upper
panel) at cell 0 min (the end of the pulse-labeling incuba-
tion), labeled apoE was higher in Ldlr cells, indicating an
apparent increased apoE synthesis. In spite of this increase
in Ldlr cells at the start of the chase incubation, after
90 min of chase there was no difference in the amount of
apoE secreted into the medium or retained within cells
between Ldlr and WT cells. This result is consistent with
the conclusion that increased LDL receptor expression
reduced the secretion and enhanced the degradation of
apoE, and with the results from experiments using J774-E3
cells in Fig. 2. The middle and lower panels of Fig. 3 show
similar analyses for the apoE4 and apoE2 isoforms. In the
case of apoE4, the amount of apoE present in cells at the
end of the pulse incubation was reduced by 34% in Ldlr
compared with WT cells. However, the rate of secretion
was reduced by 80% and cell retention was reduced by
50%. In apoE2-expressing cells, Ldlr cells contained more
labeled apoE after the pulse incubation and demonstrated
Fig. 2. Effect of simvastatin on the secretion and retention of
newly synthesized apoE in J774-E cells. J774-E cells were pulse-
labeled, and at 60 and 120 min chase times the percentage apoE
secreted or retained in the cell was determined as described in
Methods. Before labeling, cells were incubated with (Simva) or
without (NA) 20 mM simvastatin for 20 h as indicated. Values shown
are means 6 SD of triplicate samples. * P , 0.05 for Simva versus
NA at each chase time.
Fig. 1. Reduction of net release of apolipoprotein E (apoE) into the medium by J774-E cells during
incubation with simvastatin. J774-E cells were incubated in 0.2% BSA alone or with simvastatin at the
concentration indicated. At the end of 24 h, medium was harvested for apoE immunoblot analysis. Values
shown are means of the duplicate determinations shown in the upper panel.
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increased apoE secretion, with no change in cell retention
of apoE. Because of the differences in labeled cellular
apoE after the pulse incubation (at cell 0 min) between
WT and Ldlr cells, we calculated the percentage secretion
in WT and Ldlr cells for each isoform (Table 1). As shown
here, in Ldlr cells there was a reduction in the secretion of
newly synthesized apoE3, from 44% to 22%, with a trend
toward statistical significance (P 5 0.08). In apoE4 cells,
the secretion of newly synthesized apoE was reduced sig-
nificantly, from 38% to 13% (P 5 0.03). For apoE2, the
secretion of newly synthesized apoE increased in Ldlr cells
compared with WT cells, from 10% to 19% (P 5 0.02).
We have shown previously that cell surface proteogly-
cans can sequester newly synthesized apoE in macro-
phages (14, 15). Cell surface proteoglycans also have been
shown to cooperate with apoE receptors to regulate lipo-
protein metabolism in other cell types (26). Therefore, we
evaluated whether modulation of apoE secretion from
macrophages by the LDL receptor involved cellular pro-
teoglycans. We chose the apoE4 isoform for evaluation, as
the effect of the LDL receptor on the secretion of this
isoform was greatest. ApoE4-expressing cells were depleted
of proteoglycans as described previously (14, 15). We
then evaluated the amount of apoE release into the me-
dium during a 2 h labeling incubation (Fig. 4). Measure-
ment of LDL receptor mRNA levels confirmed that a 3- to
4-fold increase was maintained in LDLr compared with
WT cells after proteoglycan depletion (data not shown).
In WT cells, depletion of proteoglycans approximately
doubled the amount of apoE released into the medium,
with no change or a slight increase in cellular apoE (Fig. 4,
upper panel). In Ldlr cells, the depletion of proteoglycans
led to an z4-fold increase of apoE secreted in the me-
dium, with no change in cellular apoE. The evaluation of
proteoglycan depletion on apoE secretion was done in
separate experiments for WT and Ldlr cells; therefore, it is
not possible to compare WT and Ldlr cells directly. How-
ever, depletion of cellular proteoglycans in Ldlr cells led to
a greater release of apoE from cells into the medium than
from WT cells. These results are consistent with cooper-
ation between cellular proteoglycans and the LDL recep-
tor for modulating apoE secretion.
The results described above indicated that increased
LDL receptor expression reduced the secretion of apoE3
and apoE4, but not apoE2, from macrophages. We pre-
viously established an important role for endogenous
apoE in modulating sterol efflux from macrophages (11,
13, 15). Therefore, we next evaluated whether the influ-
ence of the LDL receptor on apoE secretion was reflected
in differences in sterol efflux from macrophages and how
this related to apoE isoform. Figure 5 shows the results of
sterol efflux experiments performed with WT and Ldlr
cells expressing human apoE2, apoE3, or apoE4. There
were no differences in total cell cholesterol mass at the
start of the efflux incubations for any of the cell types
TABLE 1. Effects of LDL receptor expression on apoE2, apoE3, and
apoE4 secretion in mouse peritoneal macrophages
Isoform WT Ldlr P
E2 10 6 3% 19 6 3% 0.02
E3 44 6 10% 22 6 7% 0.08
E4 38 6 9% 13 6 4% 0.03
apoE, apolipoprotein E; Ldlr, macrophages with increased low
density lipoprotein receptor expression; WT, macrophages with basal
low density lipoprotein expression. The percentage of apoE secreted
for each isoform was calculated as described in Methods.
Fig. 3. Regulation of apoE secretion by the LDL receptor. Mouse
peritoneal macrophages (MPMs) expressing human apoE3 (upper
panel), apoE4 (middle panel), or apoE2 (lower panel) were har-
vested and cultured as described in Methods. The synthesis and
secretion of apoE was measured using a pulse-chase analysis in cells
with basal (WT) or increased (Ldlr) LDL receptor expression, as
described in Methods. Values shown are means 6 SD of triplicate
samples. * P , 0.05 for WT versus Ldlr cells.
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compared. Increased expression of the LDL receptor re-
duced sterol efflux from macrophages expressing apoE3
and apoE4, similar to the effects of increased LDL recep-
tor on apoE secretion. For the apoE2 isoform, the cells
with increased LDL receptor expression showed slightly
more efflux than WT cells, also consistent with changes
in apoE2 secretion observed in Ldlr cells. Time points up
to 120 min are presented in Fig. 5; however, differences
between WT and Ldlr cells were maintained for up to 24 h
data not shown).
DISCUSSION
Increased LDL receptor expression by the liver, such as
that resulting from statin administration, leads to in-
creased hepatic uptake and degradation of LDL particles
with a subsequent decline in circulating LDL cholesterol
level. Reducing LDL cholesterol level produces a signifi-
cant atheroprotective effect in both animals and humans.
Relevant to our current observations, it has also been dem-
onstrated that increased LDL receptor expression leads to
the decreased secretion of apoB by hepatocytes (27). In
this report, we provide evidence that the LDL receptor
also regulates apoE secretion by macrophages.
The expression of apoE by macrophages is regulated
by multiple pathways at transcriptional and posttranscrip-
tional loci. Macrophage differentiation state, inflammatory
cytokines, interaction with components of the extracellular
matrix, and the availability of extracellular lipoproteins
all modulate apoE synthesis and secretion by macrophages
(4–9, 28). Importantly, macrophage free cholesterol con-
tent has large effects on macrophage apoE synthesis by
working at both transcriptional and posttranslational loci
(4–6, 10). Macrophage sterol content directly influences
apoE gene transcription via a liver X receptor element
found in downstream enhancer (4–6). Macrophage sterol
content also stabilizes newly synthesized apoE, as demon-
strated in cells with constitutive expression of an apoE
cDNA (10). Endogenously expressed apoE in macrophages
is also sequestered at the macrophage plasma membrane by
cell surface proteoglycans (14, 15). We have shown pre-
viously that modulating the expression of cellular proteo-
glycans influences the secretion of newly synthesized apoE
from the macrophage (14, 15). The LDL receptor at the cell
surface also binds newly synthesized apoE, and apoE bound
here can serve as an immediate precursor of secreted apoE
(16). This observation raised the possibility that the level
of LDL receptor expression would also influence the secre-
tion of newly synthesized apoE.
Increasing LDL receptor expression using statins, or by
expressing an LDL receptor mRNA species with increased
stability, reduces apoE secretion from macrophages. This
regulation of apoE secretion by the LDL receptor would
allow for the rapid coordination of two homeostatic path-
ways involved in defending macrophage sterol balance.
Changes in macrophage sterol content regulate the ex-
pression of the LDL receptor and apoE in opposite di-
rections (29). With decreasing cholesterol content, or an
increased need for cellular cholesterol, increased expres-
sion of the LDL receptor leads to increased internaliza-
tion of cholesterol-containing lipoproteins. On the other
hand, a net surplus of cell cholesterol leads to increased
expression of apoE, which facilitates net sterol efflux from
cells, and, therefore, to a net reduction in cellular sterol
content. After migration of monocytes from the circulation
to sites of tissue injury or inflammation, these cells likely
undergo large variations in sterol content relative to need.
The process of conversion to fully mature macrophages re-
quires a dramatic expansion of the plasma membrane,
which imposes a significant need for additional cellular cho-
lesterol. Membrane expansion and turnover in fully mature
macrophages will also be influenced by activation state and
by phagocytic activity. On the other hand, the ingestion of
apoptotic cells or modified lipoproteins can lead to sub-
stantial increases in macrophage cholesterol content. The
ability of macrophages to rapidly coordinate the expression
of two pathways with opposite effects on cellular sterol flux
may be central to preserving cellular sterol balance.
Fig. 4. Effect of proteoglycan depletion on LDL receptor modu-
lation of apoE4 secretion. MPMs expressing human apoE4 with
basal (WT) or increased (Ldlr) LDL receptor expression were
treated with 1 mM 4-methyl-umbelliferyl-b-D-xyloside for 72 h in
DMEM/10% FBS (PG2) or maintained in 10% FBS (PG1). Thirty
minutes before incubation with [35S]methionine, cells that were
preincubated with 4-methyl-umbelliferyl-b-D-xyloside were also
treated with 3 U/ml heparinase in 0.1% BSA/DMEM at 378C.
Control cells were placed in 0.1% BSA/DMEM only. Cells were
then incubated with [35S]methionine (50 mCi/ml) with 1 mM cold
methionine at 378C for 120 min. At that time, cell lysates and media
were harvested for quantitative immunoprecipitation of apoE, as
described in Methods. Values shown are means 6 SD of triplicate
samples. * P , 0.05 for PG1 versus PG2 cells.
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The influence of LDL receptor expression on apoE
secretion that we observed was isoform-dependent, and the
effect paralleled the established affinity of each apoE
isoform for binding to the LDL receptor (17, 18). ApoE2
binds to the LDL receptor with much less affinity than
apoE3 or apoE4, and increased LDL receptor expression
did not decrease apoE2 secretion from macrophages. The
increase in apoE secretion we measured in apoE2 Ldlr cells
compared with apoE2 WT cells may be related to the much
higher initial level of synthesis observed in Ldlr cells.
ApoE4 binds to the LDL receptor with equal or higher
affinity than apoE3. In our experiments, the reduction of
apoE4 secretion with increased LDL receptor expression
was the most easily detectable. The reduction of apoE3
secretion in Ldlr cells did not reach statistical significance,
partly because initial apoE3 synthesis was also lower in
apoE3 Ldlr cells. The results of experiments with J774-E
cells, however, which constitutively express a human apoE3
cDNA (and therefore do not present the confounding
problem of differences in initial apoE3 synthesis rates),
showed that increased LDL receptor expression did de-
crease apoE3 secretion. The isoform dependence of the
effect of the LDL receptor on apoE secretion strongly
suggests that changes in apoE secretion require a direct
interaction between apoE and the LDL receptor. This con-
clusion is also consistent with our previous observations
that apoE is sequestered at the macrophage cell surface
and can be displaced by the addition of monoclonal or
polyclonal antisera to the LDL receptor at 48C (16). Binding
to cell surface proteoglycans also influences apoE secre-
tion from macrophages (14, 15). Cullen et al. (30) previ-
ously reported that apoE4 has the highest affinity of the
apoE isoforms for macrophage cell surface proteoglycans.
Our results indicate that the effect of the LDL receptor
on apoE4 secretion depends on the presence of an intact
complement of cellular proteoglycans.
In our experiments, it was interesting that the amount
of labeled apoE present within cells immediately after
pulse-labeling was different between WT and Ldlr cells
for all of the apoE isoforms. Although these differences
could represent true changes in initial synthesis, we can-
not rule out some contribution of differences in a very
rapid initial degradation process. This problem can usu-
ally be addressed by shortening pulse-labeling times; how-
ever, this was impractical in our studies because of the
very low secretion rates for some of the apoE isoforms,
leading to difficulty in reliably measuring secreted apoE
with shorter labeling times. The basis for the differences
between WT and Ldlr cells immediately after pulse-
labeling will require additional work. It is also important
to recognize that the results of our experiments do not
distinguish between the effects of an overall increase in
LDL receptor expression and an increase in human LDL
receptor expression.
The results in this report not only show that the LDL
receptor is involved in regulating the secretion of apoE
from macrophages but, importantly, also demonstrate
that the LDL receptor expression level regulates apoE-
dependent sterol efflux from macrophages. The changes
in apoE-mediated sterol efflux produced by increased
LDL receptor expression paralleled the LDL receptor-
mediated changes in apoE secretion. In conclusion, the
regulation of apoE secretion and apoE-mediated sterol
efflux by the LDL receptor establishes a regulatory interac-
tion between two branches of macrophage sterol homeo-
static pathways. This interaction would allow macrophages
to rapidly respond to changes in sterol flux that occur as
part of their differentiated function.
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